ARCA biopharma, Inc. (ABIO) financial statements (2020 and earlier)

Company profile

Business Address 11080 CIRCLEPOINT ROAD
WESTMINSTER, CO 80020
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1071221391517
Cash and cash equivalents10797391517
Short-term investments  314   
Other current assets0010000
Total current assets:1071221391517
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000000
Long-term investments and receivables   2   
Long-term investments   2   
Other noncurrent assets0001110
Total noncurrent assets:0003110
TOTAL ASSETS:1071225401617
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1122211
Accounts payable0011011
Accrued liabilities10100  
Employee-related liabilities0011100
Other liabilities     00
Total current liabilities:1122212
Noncurrent Liabilities
Liabilities, other than long-term debt  00 00
Deferred revenue and credits00 00
Total noncurrent liabilities:  00 00
Total liabilities:1122212
Stockholders' equity
Stockholders' equity attributable to parent961022381516
Common stock0000000
Additional paid in capital1521451411351349990
Accumulated other comprehensive loss  (0)(0)   
Accumulated deficit(143)(139)(131)(113)(96)(85)(75)
Total stockholders' equity:961022381516
TOTAL LIABILITIES AND EQUITY:1071225401617

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(6)(8)(19)(17)(11)(10)(7)
Other undisclosed operating income     0 
Operating loss:(6)(8)(19)(17)(11)(10)(7)
Interest and debt expense(0)(0)(0) (0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes      0
Loss from continuing operations before equity method investments, income taxes:(6)(8)(19)(17)(11)(10)(7)
Other undisclosed income from continuing operations before income taxes000    
Loss from continuing operations before income taxes:(6)(8)(19)(17)(11)(10)(7)
Income tax benefit000    
Net loss:(6)(8)(18)(17)(11)(10)(7)
Other undisclosed net income attributable to parent   000 
Net loss attributable to parent:(6)(8)(18)(16)(11)(10)(7)
Preferred stock dividends and other adjustments      (2)
Net loss available to common stockholders, diluted:(6)(8)(18)(16)(11)(10)(9)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(6)(8)(18)(17)(11)(10)(7)
Comprehensive loss:(6)(8)(18)(17)(11)(10)(7)
Other undisclosed comprehensive income, net of tax, attributable to parent 000   
Comprehensive loss, net of tax, attributable to parent:(6)(8)(18)(16)(11)(10)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: